<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258488</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2020-01</org_study_id>
    <nct_id>NCT04258488</nct_id>
  </id_info>
  <brief_title>Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement</brief_title>
  <acronym>RENOVATE</acronym>
  <official_title>Randomized, Evaluation of Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joon Bum Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the long-term anticoagulation with oral factor Xa inhibitor versus
      vitamin K antagonist in patients receiving a mechanical aortic valve replacement.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With clinically relevant bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Composite significant Bleeding Endpoint</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With clinically relevant bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>BARC (Bleeding Academic Research Consortium) 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With clinically relevant bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>BARC (Bleeding Academic Research Consortium) 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With clinically relevant bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>BARC (Bleeding Academic Research Consortium) 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With composite event</measure>
    <time_frame>1 year</time_frame>
    <description>composite event: all cause death, stroke, systemic embolism, transient ischemic attack, or myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With all cause death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With cadiovascular death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With composite event</measure>
    <time_frame>1 year</time_frame>
    <description>composite event: stroke, systemic embolism, transient ischemic attack, or myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With systemic embolism</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With transient ischemic attack</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With significant bleeding event</measure>
    <time_frame>1 year</time_frame>
    <description>BARC (Bleeding Academic Research Consortium) 3 or 5 Bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With leaflet thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>confirmed on transthoracic echocardiogram, transesophageal echocardiogram, cinefluoroscopy or autopsy according to Valve Academic Research Consortium(VARC) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of echocardiographic parameter</measure>
    <time_frame>1 year</time_frame>
    <description>Integral ratio at baseline and 1 year follow-up : transaortic valve mean gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of echocardiographic parameter</measure>
    <time_frame>1 year</time_frame>
    <description>Integral ratio at baseline and 1 year follow-up : transaortic valve peak gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of echocardiographic parameter</measure>
    <time_frame>1 year</time_frame>
    <description>Integral ratio at baseline and 1 year follow-up : transaortic valve peak velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of echocardiographic parameter</measure>
    <time_frame>1 year</time_frame>
    <description>Integral ratio at baseline and 1 year follow-up : effective orifice area(EOA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>AORTIC VALVE DISEASES</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Oral Factor Xa inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K antagonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban Oral Tablet</intervention_name>
    <description>Apixaban oral tablet 5mg bid
If age≥80, weight≤60kg, Creatinine≥1.5mg/dl OR moderate or severe renal dysfunction, Apixaban 2.5mg bid</description>
    <arm_group_label>Oral Factor Xa inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K antagonist(warfarin)</intervention_name>
    <description>Keep the international normalized ratio (INR) 2.0-3.0</description>
    <arm_group_label>Vitamin K antagonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19 and more

          -  At least 3months after mechanical aortic valve replacement

          -  According to the Valve Academic Research Consortium(VARC)-2 criteria, confirmed proper
             valve function: no prosthesis-patient mismatch∗ and mean aortic valve gradient &lt;20 mm
             Hg or peak velocity &lt;3 m/s, AND no moderate or severe prosthetic valve regurgitation

          -  Voluntarily participated in the written agreement

        Exclusion Criteria:

          -  Old generation mechanical valve

          -  History of hemorrhagic stroke

          -  Clinically overt stroke within the last 3 months

          -  Renal failure(creatinine clearance &lt;15mL/min) or on hemodialysis

          -  Left ventricular dysfunction: Left ventricular ejection fraction (LVEF) ≤40%

          -  Moderate and severe hepatic impairment, and any hepatic disease associated with
             coagulopathy

          -  The increased risk of bleeding due to the following reasons:

               -  History of gastrointestinal ulcers

               -  History of intracranial or intracerebral haemorrhage

               -  Spinal cord vascular abnormalities or intracerebral vascular abnormalities

               -  History of the brain, spinal cord or ophthalmic surgery

               -  History of the brain or spinal cord injury

               -  Esophageal varices

               -  Arteriovenous malformation

               -  Vascular aneurysms

               -  Malignant tumor with a high risk of bleeding

          -  Uncontrolled moderate or severe hypertension

          -  Gastrointestinal bleeding within 1year

          -  Hemoglobin level &lt;10.0 g/dL or platelet count &lt; 100 x 109/L

          -  Infective endocarditis

          -  Hypersensitivity to the main component or constituents of Apixaban or Vitamin K
             antagonist

          -  Positive pregnancy test results (all pregnant women should undergo urinary human
             chorionic gonadotropin (hCG) testing within 7 days prior to screening and/or
             randomization) or during pregnancy or lactation

          -  Moderate to severe mitral stenosis

          -  A genetic problem with galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption

          -  The unsuitable condition to the protocol

          -  Actively participating in another drug or device investigational study, which has not
             completed the primary endpoint follow-up period

          -  Terminal illness with life expectancy &lt;12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-min Ahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>drjmahn@gmail.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-hee Ham, RN</last_name>
    <phone>82230104728</phone>
    <email>cvcrc5@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Joon Bum Kim, MD</last_name>
      <phone>82-2-3010-5416</phone>
      <email>jbkim1975@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Joon-bum Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Bum Kim</investigator_full_name>
    <investigator_title>Professor, Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine</investigator_title>
  </responsible_party>
  <keyword>Aortic valve replacement</keyword>
  <keyword>Mechanical valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

